<DOC>
	<DOC>NCT02628860</DOC>
	<brief_summary>This phase II study is to evaluate the safety and efficacy of Ferinject® in reducing perioperative transfusion in iron deficiency anemia patients anticipating pancreatoduodenectomy.</brief_summary>
	<brief_title>Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy</brief_title>
	<detailed_description>Primary objectives : Perioperative transfusion rate (including preop, intraop, postop≦7 days). Secondary objectives : Postoperative complication, hospital stay, change of hematological parameters (Hb, ferritin, transferrin saturation (TSAT) change after Ferinject® injection), adverse effect with Ferinject® injection.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>≥19 years old anticipating PD preoperative Hb of Female 7.011.9g/dl and Male 7.012.9g/dl signed written informed consent a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient hypersensitivity to any component of the formulation active severe infection/inflammation history of transfusion, erythropoietin, &gt;500 mg intravenous iron administration within 4 weeks prior to screening. history of acquired iron overload. MCV &gt; 95µm3 or TSAT &gt; 35% patients with preoperative Hb&lt;7 g/dl pregnancy or lactation decreased renal function (defined as creatinine clearance &lt;50 L/min/1.73m2calculated by eGFR(MDRD)) chronic liver disease or increase of liver enzymes (ALT, AST) &gt;5 times the upper limit of normal range</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ferric carboxymaltose</keyword>
	<keyword>Ferinject®</keyword>
	<keyword>pancreatoduodenectomy</keyword>
</DOC>